{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:41:32Z","timestamp":1792453292130,"version":"4.5.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:00:00Z","timestamp":1790640000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005634","name":"Suomen Hammasl\u00e4\u00e4k\u00e4riseura Apollonia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005634","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012682","name":"Oulun Yliopiston Tukis\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012682","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Oral Invest"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>This study evaluated the incidence of MRONJ and associated factors among breast cancer patients with bone metastases in Finland.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Materials and methods<\/jats:title>\n                    <jats:p>This retrospective cohort study included all adult patients with breast cancer and bone metastases who were prescribed antiresorptive therapy between 2013 and 2015. Patients were identified from national health care registers and followed through 2020. The outcome variable was MRONJ (M87.1). Covariates included age, oral diseases, dental procedures, type of antiresorptive (AR) prescribed, comorbidities, and concomitant medications.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 652 patients met the inclusion criteria. The incidence of MRONJ ranged from 0% to 2.2% among bisphosphonate users, compared with 12.6% among denosumab users and 15.3% among patients receiving sequential bisphosphonate and denosumab therapy. Both denosumab monotherapy and sequential bisphosphonate-denosumab therapy were associated with substantially increased MRONJ risk compared with bisphosphonate therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Denosumab use and infection-related invasive dental procedures showed the strongest associations with MRONJ in this study population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Clinical relevance<\/jats:title>\n                    <jats:p>MRONJ incidence differed by type of antiresorptive therapy, with higher occurrence among patients using denosumab or bisphoshonates followed by denosumab compared with bisphosphonates. MRONJ was more frequent among patients who underwent infection-related invasive dental procedures.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s00784-026-07171-5","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T06:44:15Z","timestamp":1790664255000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Incidence and associated factors of medication-related osteonecrosis of the jaw in breast cancer patients with bone metastases: a nationwide registry study in Finland"],"prefix":"10.1007","volume":"30","author":[{"given":"Miika","family":"Kujanp\u00e4\u00e4","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ville","family":"Vuollo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Antti","family":"Tiisanoja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marja-Liisa","family":"Laitala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jussi","family":"Koivunen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George K.","family":"S\u00e1ndor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saujanya","family":"Karki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,9,29]]},"reference":[{"key":"7171_CR1","unstructured":"World Health Organization (2024) Breast cancer. https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/breast-cancer. Accessed 5 Jul 2025"},{"key":"7171_CR2","doi-asserted-by":"publisher","first-page":"209","DOI":"10.3322\/caac.21660","volume":"71","author":"H Sung","year":"2021","unstructured":"Sung H, Ferlay J, Siegel RL et al (2021) Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin 71:209\u2013249. https:\/\/doi.org\/10.3322\/caac.21660","journal-title":"CA Cancer J Clin"},{"key":"7171_CR3","unstructured":"Finnish Cancer Registry (2022) Finnish Cancer Registry 2022. https:\/\/syoparekisteri.fi\/assets\/themes\/ssy3\/factsheets\/cancer_in_finland_2022.html. Accessed 5 Jul 2025"},{"key":"7171_CR4","doi-asserted-by":"publisher","first-page":"4559","DOI":"10.1158\/1078-0432.CCR-03-0325","volume":"10","author":"T Hiraga","year":"2004","unstructured":"Hiraga T, Williams PJ, Ueda A et al (2004) Zoledronic Acid Inhibits Visceral Metastases in the 4T1\/luc Mouse Breast Cancer Model. Clin Cancer Res 10:4559\u20134567. https:\/\/doi.org\/10.1158\/1078-0432.CCR-03-0325","journal-title":"Clin Cancer Res"},{"key":"7171_CR5","doi-asserted-by":"publisher","first-page":"631","DOI":"10.1007\/s00223-023-01078-z","volume":"112","author":"MR Moshi","year":"2023","unstructured":"Moshi MR, Nicolopoulos K, Stringer D et al (2023) The Clinical Effectiveness of Denosumab (Prolia\u00ae) for the Treatment of Osteoporosis in Postmenopausal Women, Compared to Bisphosphonates, Selective Estrogen Receptor Modulators (SERM), and Placebo: A Systematic Review and Network Meta-Analysis. Calcif Tissue Int 112:631\u2013646. https:\/\/doi.org\/10.1007\/s00223-023-01078-z","journal-title":"Calcif Tissue Int"},{"key":"7171_CR6","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1200\/JCO.21.02647","volume":"40","author":"A Eisen","year":"2022","unstructured":"Eisen A, Somerfield MR, Accordino MK et al (2022) Use of Adjuvant Bisphosphonates and Other Bone-Modifying Agents in Breast Cancer: ASCO-OH (CCO) Guideline Update. J Clin Oncol 40:787\u2013800. https:\/\/doi.org\/10.1200\/JCO.21.02647","journal-title":"J Clin Oncol"},{"key":"7171_CR7","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1016\/j.joms.2014.04.031","volume":"72","author":"SL Ruggiero","year":"2014","unstructured":"Ruggiero SL, Dodson TB, Fantasia J et al (2014) American Association of Oral and Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of the Jaw\u20142014 Update. J Oral Maxillofac Surg 72:1938\u20131956. https:\/\/doi.org\/10.1016\/j.joms.2014.04.031","journal-title":"J Oral Maxillofac Surg"},{"key":"7171_CR8","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.joms.2022.02.008","volume":"80","author":"SL Ruggiero","year":"2022","unstructured":"Ruggiero SL, Dodson TB, Aghaloo T et al (2022) American Association of Oral and Maxillofacial Surgeons\u2019 Position Paper on Medication-Related Osteonecrosis of the Jaws\u20142022 Update. J Oral Maxillofac Surg 80:920\u2013943. https:\/\/doi.org\/10.1016\/j.joms.2022.02.008","journal-title":"J Oral Maxillofac Surg"},{"key":"7171_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1016\/j.jcms.2017.11.008","volume":"46","author":"VL do N Poubel","year":"2018","unstructured":"do N Poubel VL, Silva CAB, Mezzomo LAM et al (2018) The risk of osteonecrosis on alveolar healing after tooth extraction and systemic administration of antiresorptive drugs in rodents: a systematic review. J Cranio-Maxillofacial Surg 46:245\u2013256. https:\/\/doi.org\/10.1016\/j.jcms.2017.11.008","journal-title":"J Cranio-Maxillofacial Surg"},{"key":"7171_CR10","doi-asserted-by":"publisher","first-page":"265","DOI":"10.4103\/ams.ams_192_18","volume":"8","author":"E Rytkonen","year":"2018","unstructured":"Rytkonen E, Ottavainen V, Rytk\u00f6nen A et al (2018) Denosumab treatment for aggressive multiple recurrent familial central giant-cell granulomas. Ann Maxillofac Surg 8:265. https:\/\/doi.org\/10.4103\/ams.ams_192_18","journal-title":"Ann Maxillofac Surg"},{"key":"7171_CR11","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1038\/sj.bdj.2017.1039","volume":"224","author":"V Patel","year":"2018","unstructured":"Patel V, Mansi J, Ghosh S et al (2018) MRONJ risk of adjuvant bisphosphonates in early stage breast cancer. Br Dent J 224:74\u201379. https:\/\/doi.org\/10.1038\/sj.bdj.2017.1039","journal-title":"Br Dent J"},{"key":"7171_CR12","doi-asserted-by":"publisher","first-page":"18317","DOI":"10.1002\/cam4.6429","volume":"12","author":"P Bracchi","year":"2023","unstructured":"Bracchi P, Zecca E, Brunelli C et al (2023) A real-world study on the prevalence and risk factors of medication related osteonecrosis of the jaw in cancer patients with bone metastases treated with Denosumab. Cancer Med 12:18317\u201318326. https:\/\/doi.org\/10.1002\/cam4.6429","journal-title":"Cancer Med"},{"key":"7171_CR13","doi-asserted-by":"publisher","unstructured":"Limones A, S\u00e1ez-Alcaide LM, D\u00edaz-Parre\u00f1o SA et al (2020) Medication-related osteonecrosis of the jaws (MRONJ) in cancer patients treated with denosumab VS. zoledronic acid: a systematic review and meta-analysis. Med Oral Patol Oral Cir Bucal e326\u2013e336. https:\/\/doi.org\/10.4317\/medoral.23324","DOI":"10.4317\/medoral.23324"},{"key":"7171_CR14","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1200\/JCO.24.00171","volume":"43","author":"C Brunner","year":"2025","unstructured":"Brunner C, Arvandi M, Marth C et al (2025) Incidence of Medication-Related Osteonecrosis of the Jaw in Patients With Breast Cancer During a 20-Year Follow-Up: A Population-Based Multicenter Retrospective Study. J Clin Oncol 43:180\u2013188. https:\/\/doi.org\/10.1200\/JCO.24.00171","journal-title":"J Clin Oncol"},{"key":"7171_CR15","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1007\/s00280-021-04262-w","volume":"87","author":"H Ikesue","year":"2021","unstructured":"Ikesue H, Doi K, Morimoto M et al (2021) Switching from zoledronic acid to denosumab increases the risk for developing medication-related osteonecrosis of the jaw in patients with bone metastases. Cancer Chemother Pharmacol 87:871\u2013877. https:\/\/doi.org\/10.1007\/s00280-021-04262-w","journal-title":"Cancer Chemother Pharmacol"},{"key":"7171_CR16","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.oooo.2020.04.808","volume":"130","author":"F Hallmer","year":"2020","unstructured":"Hallmer F, Bjarnadottir O, G\u00f6trick B et al (2020) Incidence of and risk factors for medication-related osteonecrosis of the jaw in women with breast cancer with bone metastasis: a population-based study. Oral Surg Oral Med Oral Pathol Oral Radiol 130:252\u2013257. https:\/\/doi.org\/10.1016\/j.oooo.2020.04.808","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"7171_CR17","doi-asserted-by":"publisher","first-page":"17377","DOI":"10.1038\/s41598-025-02225-2","volume":"15","author":"M Kujanp\u00e4\u00e4","year":"2025","unstructured":"Kujanp\u00e4\u00e4 M, Vuollo V, Tiisanoja A et al (2025) Incidence of medication-related osteonecrosis of the jaw and associated antiresorptive drugs in adult Finnish population. Sci Rep 15:17377. https:\/\/doi.org\/10.1038\/s41598-025-02225-2","journal-title":"Sci Rep"},{"key":"7171_CR18","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/odi.12708","volume":"24","author":"K McGowan","year":"2018","unstructured":"McGowan K, McGowan T, Ivanovski S (2018) Risk factors for medication-related osteonecrosis of the jaws: A systematic review. Oral Dis 24:527\u2013536. https:\/\/doi.org\/10.1111\/odi.12708","journal-title":"Oral Dis"},{"key":"7171_CR19","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1002\/jbmr.2405","volume":"30","author":"AA Khan","year":"2015","unstructured":"Khan AA, Morrison A, Hanley DA et al (2015) Diagnosis and Management of Osteonecrosis of the Jaw: A Systematic Review and International Consensus. J Bone Miner Res 30:3\u201323. https:\/\/doi.org\/10.1002\/jbmr.2405","journal-title":"J Bone Miner Res"},{"key":"7171_CR20","doi-asserted-by":"publisher","first-page":"386","DOI":"10.1097\/COC.0b013e3182155fcb","volume":"35","author":"V Thumbigere-Math","year":"2012","unstructured":"Thumbigere-Math V, Tu L, Huckabay S et al (2012) A Retrospective Study Evaluating Frequency and Risk Factors of Osteonecrosis of the Jaw in 576 Cancer Patients Receiving Intravenous Bisphosphonates. Am J Clin Oncol 35:386\u2013392. https:\/\/doi.org\/10.1097\/COC.0b013e3182155fcb","journal-title":"Am J Clin Oncol"},{"key":"7171_CR21","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1007\/s00109-024-02425-9","volume":"102","author":"G Bassan Marinho Maciel","year":"2024","unstructured":"Bassan Marinho Maciel G, Marinho Maciel R, Linhares Ferrazzo K, Cademartori Danesi C (2024) Etiopathogenesis of medication-related osteonecrosis of the jaws: a review. J Mol Med 102:353\u2013364. https:\/\/doi.org\/10.1007\/s00109-024-02425-9","journal-title":"J Mol Med"},{"key":"7171_CR22","doi-asserted-by":"publisher","first-page":"1172","DOI":"10.1210\/jc.2006-2036","volume":"92","author":"M Khamaisi","year":"2007","unstructured":"Khamaisi M, Regev E, Yarom N et al (2007) Possible Association between Diabetes and Bisphosphonate-Related Jaw Osteonecrosis. J Clin Endocrinol Metab 92:1172\u20131175. https:\/\/doi.org\/10.1210\/jc.2006-2036","journal-title":"J Clin Endocrinol Metab"},{"key":"7171_CR23","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1634\/theoncologist.2011-0202","volume":"17","author":"P Nicoletti","year":"2012","unstructured":"Nicoletti P, Cartsos VM, Palaska PK et al (2012) Genomewide Pharmacogenetics of Bisphosphonate-Induced Osteonecrosis of the Jaw: The Role of RBMS3. Oncologist 17:279\u2013287. https:\/\/doi.org\/10.1634\/theoncologist.2011-0202","journal-title":"Oncologist"},{"key":"7171_CR24","unstructured":"Finlex (2019) Laki sosiaali- ja terveystietojen toissijaisesta k\u00e4yt\u00f6st\u00e4. In: Laki sosiaali- ja terveystietojen toissijaisesta k\u00e4yt\u00f6st\u00e4. https:\/\/www.finlex.fi\/en\/legislation\/2019\/552#Text%20of%20statute. Accessed 26 Mar 2024"},{"key":"7171_CR25","unstructured":"World Health Organization (n.d.b) Anatomical Therapeutic Chemical (ATC) Classification"},{"key":"7171_CR26","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/j.oooo.2018.08.015","volume":"126","author":"F Hallmer","year":"2018","unstructured":"Hallmer F, Andersson G, G\u00f6trick B et al (2018) Prevalence, initiating factor, and treatment outcome of medication-related osteonecrosis of the jaw\u2014a 4-year prospective study. Oral Surg Oral Med Oral Pathol Oral Radiol 126:477\u2013485. https:\/\/doi.org\/10.1016\/j.oooo.2018.08.015","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol"},{"key":"7171_CR27","doi-asserted-by":"publisher","first-page":"251","DOI":"10.1007\/s00223-017-0369-x","volume":"102","author":"C Handforth","year":"2018","unstructured":"Handforth C, D\u2019Oronzo S, Coleman R, Brown J (2018) Cancer Treatment and Bone Health. Calcif Tissue Int 102:251\u2013264. https:\/\/doi.org\/10.1007\/s00223-017-0369-x","journal-title":"Calcif Tissue Int"},{"key":"7171_CR28","doi-asserted-by":"publisher","first-page":"1650","DOI":"10.1016\/j.annonc.2020.07.019","volume":"31","author":"R Coleman","year":"2020","unstructured":"Coleman R, Hadji P, Body J-J et al (2020) Bone health in cancer: ESMO Clinical Practice Guidelines. Ann Oncol 31:1650\u20131663. https:\/\/doi.org\/10.1016\/j.annonc.2020.07.019","journal-title":"Ann Oncol"},{"key":"7171_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1007\/s11864-021-00835-2","volume":"22","author":"A Diana","year":"2021","unstructured":"Diana A, Carlino F, Giunta EF et al (2021) Cancer Treatment\u2013Induced Bone Loss (CTIBL): State of the Art and Proper Management in Breast Cancer Patients on Endocrine Therapy. Curr Treat Options Oncol 22:45. https:\/\/doi.org\/10.1007\/s11864-021-00835-2","journal-title":"Curr Treat Options Oncol"},{"key":"7171_CR30","doi-asserted-by":"publisher","first-page":"60","DOI":"10.1016\/S1470-2045(19)30687-4","volume":"21","author":"R Coleman","year":"2020","unstructured":"Coleman R, Finkelstein DM, Barrios C et al (2020) Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol 21:60\u201372. https:\/\/doi.org\/10.1016\/S1470-2045(19)30687-4","journal-title":"Lancet Oncol"},{"key":"7171_CR31","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/S1470-2045(14)70302-X","volume":"15","author":"R Coleman","year":"2014","unstructured":"Coleman R, Cameron D, Dodwell D et al (2014) Adjuvant zoledronic acid in patients with early breast cancer: final efficacy analysis of the AZURE (BIG 01\/04) randomised open-label phase 3 trial. Lancet Oncol 15:997\u20131006. https:\/\/doi.org\/10.1016\/S1470-2045(14)70302-X","journal-title":"Lancet Oncol"},{"key":"7171_CR32","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","volume":"18","author":"A Valachis","year":"2013","unstructured":"Valachis A, Polyzos NP, Coleman RE et al (2013) Adjuvant Therapy With Zoledronic Acid in Patients With Breast Cancer: A Systematic Review and Meta-Analysis. Oncologist 18:353\u2013361. https:\/\/doi.org\/10.1634\/theoncologist.2012-0261","journal-title":"Oncologist"},{"key":"7171_CR33","doi-asserted-by":"publisher","first-page":"2341","DOI":"10.1007\/s00520-021-06634-7","volume":"30","author":"H Ikesue","year":"2022","unstructured":"Ikesue H, Doi K, Morimoto M et al (2022) Risk evaluation of denosumab and zoledronic acid for medication-related osteonecrosis of the jaw in patients with bone metastases: a propensity score\u2013matched analysis. Support Care Cancer 30:2341\u20132348. https:\/\/doi.org\/10.1007\/s00520-021-06634-7","journal-title":"Support Care Cancer"},{"key":"7171_CR34","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1111\/scd.12893","volume":"44","author":"I Khan","year":"2024","unstructured":"Khan I (2024) Medication-related osteonecrosis of the external auditory canal \u2013 A rapid review of the literature and relevance to special care dentists. Spec Care Dentist 44:314\u2013327. https:\/\/doi.org\/10.1111\/scd.12893","journal-title":"Spec Care Dentist"},{"key":"7171_CR35","doi-asserted-by":"publisher","unstructured":"Fusco V, Cabras M, Erovigni F et al (2021) A multicenter observational study on Medication-Related Osteonecrosis of the Jaw (MRONJ) in advanced cancer and myeloma patients of a cancer network in North-Western Italy. Med Oral Patol Oral Cir Bucal e466\u2013e473. https:\/\/doi.org\/10.4317\/medoral.24318","DOI":"10.4317\/medoral.24318"},{"key":"7171_CR36","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S0140-6736(15)60908-4","volume":"386","author":"Early Breast Cancer Trialists\u2019 Collaborative Group","year":"2015","unstructured":"Early Breast Cancer Trialists\u2019 Collaborative Group (2015) Adjuvant bisphosphonate treatment in early breast cancer: meta-analyses of individual patient data from randomised trials. Lancet 386:1353\u20131361. https:\/\/doi.org\/10.1016\/S0140-6736(15)60908-4","journal-title":"Lancet"}],"container-title":["Clinical Oral Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-026-07171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00784-026-07171-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00784-026-07171-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T23:05:17Z","timestamp":1792451117000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00784-026-07171-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,29]]},"references-count":36,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,10]]}},"alternative-id":["7171"],"URL":"https:\/\/doi.org\/10.1007\/s00784-026-07171-5","relation":{},"ISSN":["1436-3771"],"issn-type":[{"value":"1436-3771","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,29]]},"assertion":[{"value":"23 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 September 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 September 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Accepted for poster presentation at the IADR General Session, March 25, 2026 (San Diego, CA).","order":2,"name":"Ethics","label":"Prior presentation","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"486"}}